Volume 3.03 | Jan 27

Mammary Cell News 3.03 January 27, 2011.
In this issue: Science News  |  Current Publications  |  Industry News  |  Policy News  |  Events Subscribe  |  Unsubscribe

TOP STORY

Purdue Team Creates ‘Engineered Organ’ Model for Breast Cancer Research  ShareThis
Researchers have reproduced portions of the female breast in a tiny slide-sized model dubbed “breast on-a-chip” that will be used to test nanomedical approaches for the detection and treatment of breast cancer. [Press release from Purdue University discussing online prepublication in Integrative Biology]

ON83_EpiCultVideo_645x110

  
SPECIAL FEATURE

A Very Sad Loss – Stem Cell Pioneer Ernest A. McCulloch Passes Away
It is with great sadness that scientists honour the life and extraordinary contributions of Dr. Ernest “Bun” McCulloch who passed away on Wednesday, January 19th, 2011. Dr. McCulloch, along with his close friend and colleague, Dr. James Till, was a pioneer in the field of stem cell research. [Canadian Stem Cell Foundation Press Release]

Facebook Cell Therapy News is now on Facebook. Join us!

Twitter Follow us on Twitter! @MammaryCell

Interested in recruiting talented individuals? Post your career opportunities in Mammary Cell News at no cost. Contact us at [email protected]




SCIENCE NEWS

Blocking Rogue Gene Could Stop the Spread of Most Cancers
Scientists have discovered a rogue gene which – if blocked by the right drugs – could stop cancer in its tracks. [Press release from the University of East Anglia discussing online prepublication in Oncogene]

Anti-Estrogen Medication Reduces Risk of Dying from Lung Cancer, Study Finds
A new study has found that tamoxifen, an anti-estrogen breast cancer medication, may reduce an individual’s risk of death from lung cancer. [Press release from ScienceDaily discussing online prepublication in Cancer]

Smoking May Be Associated with Increased Risk of Breast Cancer
Researchers found that heavy and prolonged smoking initiated before menopause may be associated with a modest increase in the risk of developing breast cancer. [Press release from Brigham and Women’s Hospital discussing online prepublication in the Archives of Internal Medicine]

ON107-MammaryWallchart-645x110_CTA_WhatsOYW



CURRENT PUBLICATIONS (Ranked by Impact Factor of the Journal)

LABORATORY RESEARCH

Cut Homeobox 1 Causes Chromosomal Instability by Promoting Bipolar Division After Cytokinesis Failure
Using tissue culture and transgenic mouse models of breast cancer, scientists report that Cut homeobox 1 causes chromosomal instability by activating a transcriptional program that prevents multipolar divisions and enables the survival of tetraploid cells that evolve to become genetically unstable and tumorigenic. [ Proc Natl Acad Sci USA]

LOXL2-Mediated Matrix Remodeling in Metastasis and Mammary Gland Involution
Researchers investigated a role for the lysyl oxidase related enzyme LOXL2 in breast cancer metastasis, in both patient samples and in vivo models. [Cancer Res]

Prediction and Genetic Demonstration of a Role for Activator E2Fs in Myc Induced Tumors
Investigators used genomic signatures to predict involvement of specific E2F transcription factors in Myc induced tumors. [Cancer Res]

Selective Targeting of Activating and Inhibitory Smads by Distinct WWP2 Ubiquitin Ligase Isoforms Differentially Modulates TGFBeta Signaling and Epithelial-Mesenchymal Transition
Scientists identify a HECT E3 ubiquitin ligase known as WWP2 (Full-length WWP2-FL), together with two WWP2 isoforms (N-terminal, WWP2-N; C-terminal WWP2-C), as novel Smad-binding partners. [Oncogene]

miR-495 Is Upregulated by E12/E47 in Breast Cancer Stem Cells, and Promotes Oncogenesis and Hypoxia Resistance via Downregulation of E-Cadherin and REDD1
Distinct from the CD44+/CD24-/low sub-population, researchers have isolated a novel PROCR+/ESA+ BCSC sub-population. To explore miRNA-regulatory mechanisms in this sub-population, they performed miRNA expression profiling and found miR-495 as the most highly upegulated miRNA in PROCR+/ESA+ cells. [Oncogene]

Epidermal Growth Factor Regulates Mcl-1 Expression Through the MAPK-Elk-1 Signaling Pathway Contributing to Cell Survival in Breast Cancer
Investigators determined the critical downstream signals responsible for the epidermal growth factor mediated increase of myeloid cell leukemia-1 (Mcl-1) and their role in cell survival. [Oncogene]

Membrane Localization of Insulin Receptor Substrate-2 (IRS-2) Is Associated with Decreased Overall Survival in Breast Cancer
Scientists examined IRS-2 expression by immunohistochemistry in normal breast tissue, benign breast lesions, and malignant breast tumors from the institutional pathology archives and a tumor microarray from a separate institution. [Breast Cancer Res Treat]

Beta-Adrenergic Receptors (Beta-AR) Regulate VEGF and IL-6 Production by Divergent Pathways in High Beta-AR-Expressing Breast Cancer Cell Lines
To examine beta-AR regulation of breast cancer pathogenesis, beta-AR density, signaling capacity, and functional responses to beta-AR stimulation were studied in four human breast adenocarcinoma cell lines. [Breast Cancer Res Treat]

Mitochondrial Proteomics Analysis of Tumorigenic and Metastatic Breast Cancer Markers
In this study, mitochondrial proteins were enriched for proteomics analysis with the state-of-the-art two-dimensional differential gel electrophoresis and matrix-assistant laser desorption ionization-time-of-flight mass spectrometry strategy to compare and identify the mitochondrial protein profiling changes between three breast cell lines with different tumorigenicity and metastasis. [Funct Integr Genomics]

Deletion of the Thrombin Cleavage Domain of Osteopontin Mediates Breast Cancer Cell Adhesion, Proteolytic Activity, Tumorgenicity, and Metastasis
To study the role of the thrombin cleavage site of osteopontin (OPN), MDA-MB-468 human breast cancer cells were stably transfected with either wildtype OPN (468-OPN), mutant OPN lacking the thrombin cleavage domain (468-deltaTC) or an empty vector (468-CON) and assessed for in vitro and in vivo functional differences in malignant/metastatic behavior. [BMC Cancer]

Breast on-a-Chip: Mimicry of the Channeling System of the Breast for Development of Theranostics
Researchers describe the engineering of a portion of a breast ductal system using polydimethylsiloxane microfluidic channels with a total volume of 0.09 microliters. [Integr Biol]

CLINICAL RESEARCH

Cigarette Smoking and the Incidence of Breast Cancer
Prospective cohort study of 111,140 participants of the Nurses’ Health Study from 1976 to 2006 for active smoking and 36,017 women from 1982 to 2006 for passive smoking. [Arch Intern Med]

Lung Cancer Mortality Risk Among Breast Cancer Patients Treated with Anti-Estrogens
The Women’s Health Initiative randomized clinical trial reported that menopausal hormone therapy increases lung cancer mortality risk. If this is true, use of anti-estrogens should be associated with decreased lung cancer mortality risk. The authors compared lung cancer incidence and mortality among breast cancer patients with and without anti-estrogen therapy. [Cancer]

Effect of Adding Gefitinib to Neoadjuvant Chemotherapy in Estrogen Receptor Negative Early Breast Cancer in a Randomized Phase II Trial
This study was designed to determine the effect of adding gefitinib to neoadjuvant epirubicin and cyclophosphamide on tumor response rates. [Breast Cancer Res Treat]

CS_645x110_UpperBanner



INDUSTRY NEWS

Halaven™ Receives CHMP Positive Opinion for Use in Metastatic Breast Cancer
Eisai Co., Ltd. announced that its United Kingdom-based subsidiary Eisai Europe, Ltd. has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for the company’s novel anticancer agent Halaven™ as a monotherapy indicated in the treatment of patients with locally advanced or metastatic breast cancer who have received at least two chemotherapeutic regimens, including an anthracycline and a taxane. [Eisai Co., Ltd. Press Release]

Breast Cancer Research Foundation of Alabama Makes its Largest Donation Yet to UAB
The Breast Cancer Research Foundation of Alabama has presented its largest annual gift to date: $400,000. This year’s contribution brings the Birmingham-based organization’s cumulative total for the University of Alabama at Birmingham (UAB) to nearly $3 million. [University of Alabama at Birmingham Press Release]




POLICY NEWS

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)




EVENTS

Visit our events page  to see a complete list of events in the mammary cell community.



JOB OPPORTUNITIES

Lab Technologist – Cell Separation (STEMCELL Technologies)

Lab Technologist – Human Embryonic and Induced Pluripotent Stem Cells (STEMCELL Technologies)

Lab Technologist – Tissue Culture (STEMCELL Technologies)

Assistant Professor (University of Pittsburgh School of Medicine, Center for Cellular and Molecular Engineering)

Postdoc (University of Houston-Center for Nuclear Receptors and Cell Signalling)

Postdoctoral Positions (Mount Sinai School of Medicine)

Recruit Top Talent
Reach more than 11,000 potential candidates by posting your organization’s career opportunities with Cell Therapy News at no cost.

Visit here to post your career opportunities.

Have we missed an important article or publication in Mammary Cell News? Click here to submit!



Comments or Suggestions? Email [email protected] with your feedback.


Learn more about Mammary Cell News: Archives  |  Events  |  Subscribe  |  Contact Us